Total lymphocyte and CD4+T-cell count changes in participants receiving islatravir (0.25mg, 0.75mg, and 2.25mg once daily) and doravirine +/- lamivudine: post hoc analysis from a phase 2b dose-ranging study (P011)
HIV MEDICINE(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要